TheraCryf
plc
("TheraCryf", the "Company" or the "Group")
Notice of Interim results and
Presentation via Investor Meet Company
Alderley Park, 14 November 2024 - TheraCryf plc (AIM: TCF), formerly Evgen Pharma plc, the
clinical stage drug development company focussing on oncology and
neuropsychiatry, announces that the
Company's unaudited interim results for the six months to 30
September 2024 will be released on Thursday 28 November
2024.
The results will be available via
the London Stock Exchange's Regulatory News Service (RNS) and on
the Investor Relations section of the Company's website:
www.theracryf.com/investors.
Huw Jones, CEO, and Toni Hänninen,
CFO will provide a live presentation via the Investor Meet Company
platform at 11am on Thursday 28 November 2024.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via the Investor Meet Company dashboard up until 27
November 2024, 09:00 GMT, or at any time during the live
presentation. Investors who already follow TheraCryf plc on the
Investor Meet Company platform will automatically be
invited.
Investors can sign up to Investor
Meet Company
HERE.
-Ends-
Enquiries
|
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315
090
enquiries@theracryf.com
|
|
Cavendish Capital Markets (NOMAD and Broker)
Geoff Nash / Teddy Whiley / Rory Sale (Corporate
Finance)
Nigel Birks / Harriet Ward
(ECM)
|
+44 (0)20
7220 0500
|
|
Vigo Consulting
Rozi
Morris
|
+44 (0)20 7390 0231
theracryf@vigoconsulting.com
|
About TheraCryf plc
TheraCryf is the clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].
The Company's strategy is to
generate compelling data sets to preclinical and/or clinical proof
of concept and partner its clinical programmes with mid-size to
large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla
SA, in neurodevelopmental disorders. The Company has sourced know
how for programmes from companies such as Shire (now
Takeda).
TheraCryf has worked with and has
ongoing collaborations with major universities and hospitals such
as the University of Manchester, La Sapienza (Università di Roma),
the Erasmus Medical Centre, Rotterdam, Kings College London and the
University of Michigan.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is quoted on AIM
in London and trades under the ticker symbol TCF. 
For further information, please
visit: www.theracryf.com
